Published in Biomaterials on September 01, 1991
Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest (1992) 1.55
Fibroblast growth factor 2 dimer with superagonist in vitro activity improves granulation tissue formation during wound healing. Biomaterials (2015) 1.41
Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci U S A (1993) 1.36
Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther (2008) 1.30
Approaches to neural tissue engineering using scaffolds for drug delivery. Adv Drug Deliv Rev (2007) 1.28
Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci U S A (2000) 1.25
Non-thermal dielectric barrier discharge plasma induces angiogenesis through reactive oxygen species. J R Soc Interface (2011) 1.24
Biodegradable elastomeric scaffolds with basic fibroblast growth factor release. J Control Release (2007) 1.21
Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors. Biomaterials (2013) 1.14
Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest (1994) 1.09
A bioactive self-assembled membrane to promote angiogenesis. Biomaterials (2010) 1.07
The effect of controlled growth factor delivery on embryonic stem cell differentiation inside fibrin scaffolds. Stem Cell Res (2008) 1.06
Hyaluronic acid-based hydrogels functionalized with heparin that support controlled release of bioactive BMP-2. Biomaterials (2012) 1.03
Nanoscale growth factor patterns by immobilization on a heparin-mimicking polymer. J Am Chem Soc (2008) 1.03
Tissue engineered scaffolds in regenerative medicine. World J Plast Surg (2014) 0.99
A heparin-mimicking polymer conjugate stabilizes basic fibroblast growth factor. Nat Chem (2013) 0.99
Engineering chemoattractant gradients using chemokine-releasing polysaccharide microspheres. Biomaterials (2011) 0.97
Synthesis of Aminooxy End-functionalized pNIPAAm by RAFT Polymerization for Protein and Polysaccharide Conjugation. Macromolecules (2009) 0.93
The effect of vascular endothelial growth factor (VEGF) presentation within fibrin matrices on endothelial cell branching. Biomaterials (2011) 0.92
Alternating release of different bioactive molecules from a complexation polymer system. Biomaterials (2008) 0.90
Dual growth factor-releasing nanoparticle/hydrogel system for cartilage tissue engineering. J Mater Sci Mater Med (2010) 0.88
Trehalose glycopolymer resists allow direct writing of protein patterns by electron-beam lithography. Nat Commun (2015) 0.87
Stability of alginate microbead properties in vitro. J Mater Sci Mater Med (2012) 0.86
The effect of desulfation of chondroitin sulfate on interactions with positively charged growth factors and upregulation of cartilaginous markers in encapsulated MSCs. Biomaterials (2013) 0.86
Localization of magnetic pills. Proc Natl Acad Sci U S A (2011) 0.84
Clinical translation of controlled protein delivery systems for tissue engineering. Drug Deliv Transl Res (2015) 0.81
Incorporation of heparin into biomaterials. Acta Biomater (2013) 0.80
Production of a recombinant human basic fibroblast growth factor with a collagen binding domain. Protoplasma (2001) 0.79
In situ loading of basic fibroblast growth factor within porous silica nanoparticles for a prolonged release. Nanoscale Res Lett (2009) 0.79
Controlled release of repifermin from polyelectrolyte complexes stimulates endothelial cell proliferation. J Pharm Sci (2009) 0.79
Protein-hydrogel interactions in tissue engineering: mechanisms and applications. Tissue Eng Part B Rev (2012) 0.78
Analytical approaches to uptake and release of hydrogel-associated FGF-2. J Mater Sci Mater Med (2009) 0.78
A heparin-mimicking reverse thermal gel for controlled delivery of positively charged proteins. J Biomed Mater Res A (2014) 0.77
A Heparin-Mimicking Block Copolymer Both Stabilizes and Increases the Activity of Fibroblast Growth Factor 2 (FGF2). Biomacromolecules (2016) 0.76
Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles. Mol Pharm (2017) 0.75
Vascular growth factor binding kinetics to the endothelial cell basement membrane, with a kinetics-based correction for substrate binding. Cytotechnology (2009) 0.75
Gelatin device for the delivery of growth factors involved in endochondral ossification. PLoS One (2017) 0.75
A multifunctional bioactive material that stimulates osteogenesis and promotes the vascularization bone marrow stem cells and their resistance to bacterial infection. PLoS One (2017) 0.75
Heparin-based hydrogels with tunable sulfation & degradation for anti-inflammatory small molecule delivery. Biomater Sci (2016) 0.75
Delivery of bFGF for Tissue Engineering by Tethering to the ECM. Biomed Res Int (2015) 0.75
Nanostructured Mineral Coatings Stabilize Proteins for Therapeutic Delivery. Adv Mater (2017) 0.75
Angiogenic factors. Science (1987) 15.22
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 10.32
Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell (1991) 8.99
Biodegradable long-circulating polymeric nanospheres. Science (1994) 7.46
Functional arteries grown in vitro. Science (1999) 6.08
A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science (1991) 5.14
Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A (1987) 4.83
Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science (1984) 4.27
A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane. Am J Pathol (1988) 3.72
High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. Proc Natl Acad Sci U S A (1989) 3.45
Large porous particles for pulmonary drug delivery. Science (1997) 3.35
Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol (1999) 3.00
New challenges in biomaterials. Science (1994) 2.85
Polymers for the sustained release of proteins and other macromolecules. Nature (1976) 2.81
Stimulation of neurite outgrowth using an electrically conducting polymer. Proc Natl Acad Sci U S A (1997) 2.74
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 2.73
Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res (1991) 2.70
Photoencapsulation of chondrocytes in poly(ethylene oxide)-based semi-interpenetrating networks. J Biomed Mater Res (2000) 2.67
Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res (2000) 2.64
Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation. Lancet (1999) 2.62
Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc Natl Acad Sci U S A (1986) 2.55
Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell (1991) 2.52
Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci U S A (1993) 2.51
Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem (1986) 2.50
Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry (1989) 2.49
Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science (1983) 2.47
Biodegradable polymer scaffolds for tissue engineering. Biotechnology (N Y) (1994) 2.47
A controlled-release microchip. Nature (1999) 2.39
Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem (1992) 2.37
Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res (1995) 2.34
Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci U S A (1993) 2.27
Novel approach to fabricate porous sponges of poly(D,L-lactic-co-glycolic acid) without the use of organic solvents. Biomaterials (1996) 2.27
Heparin affinity of anionic and cationic capillary endothelial cell growth factors: analysis of hypothalamus-derived growth factors and fibroblast growth factors. Proc Natl Acad Sci U S A (1985) 2.21
Enzymatic degradation of glycosaminoglycans. Crit Rev Biochem Mol Biol (1995) 2.21
Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci U S A (1991) 2.19
Bioreactor cultivation conditions modulate the composition and mechanical properties of tissue-engineered cartilage. J Orthop Res (1999) 2.19
Heparin-binding EGF-like growth factor. Biochim Biophys Acta (1997) 2.19
Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell (1998) 2.17
Lipid-based nanotherapeutics for siRNA delivery. J Intern Med (2010) 2.15
Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem (1996) 2.12
Formulation and physical characterization of large porous particles for inhalation. Pharm Res (1999) 2.10
Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem (1995) 2.09
Ultrasound-mediated transdermal protein delivery. Science (1995) 2.07
Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature (1988) 2.04
Dynamic cell seeding of polymer scaffolds for cartilage tissue engineering. Biotechnol Prog (1998) 2.03
Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J (1997) 2.02
Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci U S A (1994) 2.02
Accelerated discovery of synthetic transfection vectors: parallel synthesis and screening of a degradable polymer library. J Am Chem Soc (2001) 2.02
Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol (1993) 2.02
Controlled release of dopamine from a polymeric brain implant: in vivo characterization. Ann Neurol (1989) 2.01
Cardiac tissue engineering: cell seeding, cultivation parameters, and tissue construct characterization. Biotechnol Bioeng (1999) 2.00
A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem (1997) 1.99
The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol (1995) 1.99
Transdermal photopolymerization for minimally invasive implantation. Proc Natl Acad Sci U S A (1999) 1.99
Isolation and characterization of a macrophage-derived heparin-binding growth factor. Cell Regul (1990) 1.96
Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell (1995) 1.96
Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric (2013) 1.94
Tissue engineering of functional cardiac muscle: molecular, structural, and electrophysiological studies. Am J Physiol Heart Circ Physiol (2001) 1.90
Purification and characterization of heparin-binding endothelial cell growth factors. J Biol Chem (1986) 1.89
Neocartilage formation in vitro and in vivo using cells cultured on synthetic biodegradable polymers. J Biomed Mater Res (1993) 1.88
Polymers for sustained macromolecule release: procedures to fabricate reproducible delivery systems and control release kinetics. J Pharm Sci (1980) 1.86
Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem (1997) 1.86
In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) foams. Biomaterials (2000) 1.85
Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc Natl Acad Sci U S A (2000) 1.84
Morphologic and mechanical characteristics of engineered bovine arteries. J Vasc Surg (2001) 1.84
Switching from differentiation to growth in hepatocytes: control by extracellular matrix. J Cell Physiol (1992) 1.79
Isolations of a cartilage factor that inhibits tumor neovascularization. Science (1976) 1.79
Identification of an inhibitor of neovascularization from cartilage. Science (1990) 1.78
Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J (2000) 1.78
Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Cell Biochem (1985) 1.77
Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension (2000) 1.77
Evolution of bone transplantation: molecular, cellular and tissue strategies to engineer human bone. Biomaterials (1996) 1.76
Creation of viable pulmonary artery autografts through tissue engineering. J Thorac Cardiovasc Surg (1998) 1.76
Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci U S A (2001) 1.76
Cytoskeletal filament assembly and the control of cell spreading and function by extracellular matrix. J Cell Sci (1995) 1.71
Endothelial cell mitogens derived from retina and hypothalamus: biochemical and biological similarities. J Cell Biol (1984) 1.69
Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1. Mol Cell Biol (1997) 1.69
T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci U S A (1994) 1.68
The shedding of membrane-anchored heparin-binding epidermal-like growth factor is regulated by the Raf/mitogen-activated protein kinase cascade and by cell adhesion and spreading. J Biol Chem (1999) 1.67
An evolutionary study of the methylation of transfer and ribosomal ribonucleic acid in prokaryote and eukaryote organisms. J Biol Chem (1973) 1.61
Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem (1999) 1.61
The stimulation of DNA synthesis and cell division in chondrocytes and 3T3 cells by a growth factor isolated from cartilage. Exp Cell Res (1977) 1.60
A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. J Pharm Sci (1997) 1.58
Laminated three-dimensional biodegradable foams for use in tissue engineering. Biomaterials (1993) 1.57
Transdermal monitoring of glucose and other analytes using ultrasound. Nat Med (2000) 1.57
Tissue engineering of cartilage in space. Proc Natl Acad Sci U S A (1997) 1.57
Selective cell transplantation using bioabsorbable artificial polymers as matrices. J Pediatr Surg (1988) 1.55
A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem (2000) 1.55
Transdermal photopolymerization of poly(ethylene oxide)-based injectable hydrogels for tissue-engineered cartilage. Plast Reconstr Surg (1999) 1.52
Long-term engraftment of hepatocytes transplanted on biodegradable polymer sponges. J Biomed Mater Res (1997) 1.51
[MRI with supermagnetic iron particles versus double-spiral CT in identification of malignant liver lesions]. Rofo (1998) 1.51
Fallopian tube torsion: laparoscopic evaluation and treatment of a rare gynecological entity. J Am Board Fam Pract (2001) 1.49
Tumor angiogenesis activity in cells grown in tissue culture. Cancer Res (1976) 1.48
Collagen in tissue-engineered cartilage: types, structure, and crosslinks. J Cell Biochem (1998) 1.47
Purification of cartilage-derived growth factor by heparin affinity chromatography. J Biol Chem (1985) 1.47
Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene (1999) 1.46